Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry, indicating a positive outlook compared to the broader market [1]. Core Insights - The report highlights a significant decline in the A-share and Hong Kong innovation drug sectors, with A-shares down 4.32% and Hong Kong shares down 5.88% in the latest week, underperforming their respective indices [2][19]. - Over the past six months, A-share innovation drugs have decreased by 4.40%, while Hong Kong innovation drugs have seen a cumulative decline of 7.26% [17][19]. - The report notes that 7 new drugs were approved in China in June, with 3 new indications also receiving approval [3][23]. Summary by Sections Market Performance - In the latest week, 14 stocks in the innovation drug sector rose, while 45 fell, with the top gainers being Frontline Bio-U (+15.82%), Nanxin Pharmaceutical (+8.85%), and Ascentage Pharma-B (+7.59%) [2][16]. - The XBI index increased by 2.21% in the same week, contrasting with the declines in A-share and Hong Kong markets [21]. Drug Approvals - In June, 5 NDA approvals were granted in the U.S., with 2 NDA approvals and 1 BLA approval in the latest week [28]. - No new drugs were approved in Europe or Japan during June [30][32]. Key Drug Developments - The report discusses the progress of innovative drugs targeting GLP-1 for diabetes, with 11 drugs approved globally, 9 in China, and 10 in Phase III clinical trials [9][10]. - The report also covers the advancements in HIV-1 capsid inhibitors, particularly lenacapavir, which has shown a 100% efficacy rate in preventing HIV infection in women with biannual injections [4]. Company-Specific Developments - Notable approvals include the launch of new drugs by companies such as Amgen, Novartis, and others, with specific indications for various cancers and chronic conditions [24][25][35].
2024年6月第四周创新药周报（附小专题 HIV-1 capsid 靶点研发概况）
Southwest Securities·2024-06-24 08:07